NH TherAguix is a biotechnology company developing nanoparticle-based theranostic products for cancer treatment. Its lead product, AGuIX, is a theranostic nano-drug designed to improve the efficacy of radiotherapy for cancer patients. The company has developed a pipeline of drugs targeting brain metastases, lung cancer, pancreatic cancer, and cervical cancer. The theranostic approach combines therapeutic and diagnostic capabilities within a single nanoparticle, enabling simultaneous treatment and imaging of Founded in 2015 and headquartered in Lyon, France, the company has raised $15.9M in Series A funding from investors including Bpifrance, Supernova Invest, Financiere Arbevel, and Omnes Capital.
← All startups
NH TherAguix
Series ANH TherAguix is a biotechnology company developing nanoparticle-based theranostic products for cancer treatment. Its lead product, AGuIX, is a theranostic nano-drug designed to improve the efficacy of radiotherapy for cancer patients. The company has developed a pipeline of drugs targeting brain metastases, lung cancer, pancreatic cancer, and cervical cancer. The theranostic approach combines therapeutic and…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drugs > Cancer,
Oncology > Drugs > Diversified
Institutional investors
BpifranceSupernova InvestFinanciere ArbevelOmnes Capital
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.